Nektar Therapeutics
Price Action
Technical Summary
EMERGING TRENDNektar Therapeutics shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is weak (RS Rating: 36), showing significant lag compared to the market leaders. Earnings growth of 50% provides fundamental context to the price action. Investors should exercise caution due to high volatility (94% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $61.29 | -0.50% | BELOW |
| 50 SMA | $74.00 | -17.59% | BELOW |
| 100 SMA | $69.28 | -11.98% | BELOW |
| 150 SMA | $62.45 | -2.36% | BELOW |
| 200 SMA | $60.74 | +0.40% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NKTR in an uptrend right now?
NKTR has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is NKTR overbought or oversold?
NKTR's RSI (14) is 39. The stock is in neutral territory, neither overbought nor oversold.
Is NKTR outperforming the market?
NKTR has a Relative Strength (RS) Rating of 36 out of 99. NKTR is currently lagging the broader market.
Where is NKTR in its 52-week range?
NKTR is trading at $60.98, which is 56% of its 52-week high ($109.00) and 52% above its 52-week low ($8.35).
How volatile is NKTR?
NKTR has a Beta of 1.40 and 52-week volatility of 94%. It's more volatile than the S&P 500 - expect bigger swings.